Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Aust Prescr ; 42(2): 56-61, 2019 Apr.
Article in English | MEDLINE | ID: mdl-31048939
4.
Intern Med J ; 49(11): 1386-1392, 2019 11.
Article in English | MEDLINE | ID: mdl-30887620

ABSTRACT

BACKGROUND: Management of acute ischaemic stroke is time critical. Reducing time to treatment with thrombolysis is strongly associated with improved outcomes in properly selected patients. However, there are barriers to ensuring timely treatment in the hospital setting. AIM: To determine if simple, no-cost protocol changes could improve time to treatment for acute ischaemic stroke at a busy tertiary hospital. METHODS: Prospectively collected routine clinical data were compared retrospectively before and after a protocol change designed to mirror the successful model from Helsinki University Central Hospital. Consecutive patients who activated a 'code stroke' (presentation consistent with acute stroke, eligible for acute stroke therapy) during working hours were included. RESULTS: Prior to the protocol change, 143 patients activated a code stroke, and 30 patients received thrombolysis. Following the protocol change, 134 patients activated a code stroke, and 14 patients received thrombolysis. The median time to administer thrombolysis was reduced from 76 min (interquartile range 54-91) to 33 min (27-44), P < 0.01. The median time to perform diagnostic computed tomography was unchanged between the two groups, 23 (14-54) min versus 22 (9-49) min, P = 0.12. However, this was reduced on subgroup analysis of patients whose arrival was pre-notified by the ambulance service, 16 (9-22) min versus 8 (4-14) min, P < 0.01. CONCLUSION: Time to treatment in acute stroke was dramatically improved with a simple intervention. This was achieved without a large stroke team or additional funding, making it highly accessible to other health services also seeking to improve their stroke service.


Subject(s)
Clinical Protocols , Stroke/therapy , Thrombolytic Therapy , Time-to-Treatment , Aged , Aged, 80 and over , Ambulances , Computed Tomography Angiography , Emergency Service, Hospital , Female , Humans , Male , Middle Aged , Retrospective Studies , Stroke/diagnostic imaging , Tertiary Care Centers
5.
J Stroke Cerebrovasc Dis ; 28(4): e5-e6, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30638944

ABSTRACT

A 54-year-old male with a history of left posterior parietal ischemic stroke, epilepsy, tobacco and marijuana smoking, and alcohol abuse, presented with acute left visual loss and diplopia. On examination, he had reduced left visual acuity and a left oculomotor nerve palsy. CT angiogram from aortic arch to circle of Willis identified extensive thrombus occluding the left common and internal carotid arteries, extending to the left ophthalmic artery. This case demonstrates acute visual loss from ophthalmic artery occlusion, and left oculomotor nerve palsy from occlusion of the inferolateral trunk of the internal carotid artery (cavernous sinus portion).


Subject(s)
Carotid Artery, Internal , Carotid Stenosis/complications , Oculomotor Nerve Diseases/etiology , Ophthalmic Artery , Ophthalmoplegia/etiology , Thrombosis/complications , Vision Disorders/etiology , Carotid Artery, Internal/diagnostic imaging , Carotid Artery, Internal/physiopathology , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/physiopathology , Cerebral Angiography/methods , Computed Tomography Angiography , Humans , Male , Middle Aged , Oculomotor Nerve Diseases/diagnosis , Oculomotor Nerve Diseases/physiopathology , Ophthalmic Artery/diagnostic imaging , Ophthalmic Artery/physiopathology , Ophthalmoplegia/diagnosis , Ophthalmoplegia/physiopathology , Thrombosis/diagnostic imaging , Thrombosis/physiopathology , Vision Disorders/diagnosis , Vision Disorders/physiopathology , Visual Acuity
6.
Front Neurol ; 10: 1390, 2019.
Article in English | MEDLINE | ID: mdl-32116981

ABSTRACT

Background: Autoimmune encephalitis (AE) is an important cause of refractory epilepsy, rapidly progressive cognitive decline, and unexplained movement disorders in adults. Whilst there is identification of an increasing number of associated autoantibodies, patients remain with a high clinical probability of autoimmune encephalitis but no associated characterized autoantibody. These patients represent a diagnostic and treatment dilemma. Objective: To evaluate routine and novel diagnostic tests of cerebrospinal fluid (CSF) in patients with a high probability of AE to attempt to identify better biomarkers of neuroinflammation. Methods: Over 18 months (2016-2018), adult patients with a high clinical probability of AE were recruited for a pilot cross-sectional explorative study. We also included viral polymerase-chain-reaction (PCR) positive CSF samples and CSF from neurology patients with "non-inflammatory" (NI) diagnoses for comparison. CSF was examined with standard investigations for encephalitis and novel markers (CSF light chains, and cytokines). Results and Conclusions: Thirty-two AE patients were recruited over 18 months. Twenty-one viral controls, 10 NI controls, and five other autoimmune neurological disease controls (AOND) were also included in the analysis. Our study found that conventional markers: presence of CSF monocytosis, oligoclonal bands, anti-neuronal immunofluorescence, and magnetic resonance imaging (MRI) changes could be suggestive of AE, but these investigations were neither sensitive nor specific. Promising novel makers of autoimmune encephalitis were the CSF cytokines IL-21 and IP10 which may provide better delineation between viral infections and autoimmune encephalitis than conventional markers, potentially leading to more immediate diagnosis and management of these patients.

7.
Int Rev Neurobiol ; 90: 107-20, 2010.
Article in English | MEDLINE | ID: mdl-20692497

ABSTRACT

The characteristic change in ultrasound signal seen in the substantia nigra in Parkinson's disease and related disorders is known as hyperechogenicity and is suggested to be a risk or state marker for these disorders. The underlying cellular basis of this change, however, is unknown. Imaging studies on Parkinson's disease patients, experimental studies on animal models, and human postmortem studies support the hypotheses that an alteration in regional iron and/or change in regional cell composition within the substantia nigra underlie this echo feature. Future quantitative postmortem studies incorporating cellular and metal analyses of the substantia nigra, in Parkinson's disease patients and healthy controls of known echogenic status during life, will be important to clarify the cellular basis of this change.


Subject(s)
Parkinson Disease/diagnostic imaging , Parkinson Disease/physiopathology , Substantia Nigra/diagnostic imaging , Substantia Nigra/physiopathology , Ultrasonography, Doppler, Transcranial/methods , Animals , Disease Models, Animal , Humans , Ultrasonography, Doppler, Transcranial/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...